Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations

Moradi A., Denkova R., Holcomb K., Rossi A., Ashourian N.

Prospective Study on Skin Aging, published in Aesthet Surg J Open Forum (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Aesthet Surg J Open Forum (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41768029
PMCID
PMC12937588
DOI
10.1093/asjof/ojag011
Citations
3

Abstract (original English)

Glucagon-like peptide-1 (GLP-1)-based therapies are increasingly used to support weight loss. However, there can be significant sequelae with regard to the aesthetics of the face and neck, including midface volume loss; temple, infraorbital, and submalar hollowing; increased skin laxity; accentuation of wrinkles and folds; and worsened skin quality. Individuals seeking nonsurgical correction of these issues are likely to become increasingly common, but treatments have not yet been widely studied in this population. The aim of this paper is to provide experience-based guidance on multimodal nonsurgical aesthetic treatment of the face and neck in patients undergoing weight loss with GLP-1-based therapies. Four clinicians with extensive experience of this patient group completed a written questionnaire and were individually interviewed. Their joint knowledge and expertise form the basis of this guidance. In addition, a PubMed literature search was conducted up to March 31, 2025. Eligibility for nonsurgical modalities does not typically differ greatly in this group compared with other aesthetic patients, but consideration should be given to the optimal timing of treatment within the weight loss journey. Multimodal approaches are usually needed based on volumizing with hyaluronic acid fillers; skin tightening with collagen-stimulating methods (such as energy-based devices); reductio

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research